Oral treatment options are trending in the field of psoriasis. Therefore, It remains to be seen whether the market, which is currently dominated by biologic drugs, will shift in the future.

The frontrunner in the field is BMS Pharmaceutical Korea's TYK2 inhibitor Sotyktu (deucravacitinib). The drug, which is a treatment for plaque psoriasis with a novel mechanism of action, has been approved in Korea and will be covered by reimbursement from next month (April).

Sotyktu is a first-in-class, selective TYK2 inhibitor. TYK2 is a critical intracellular transduction link between interleukin (IL)-23 and the production of IL-17, which is known to play a central role in the pathogenesis of psorias